Carter Todd Alfred 4
4 · Voyager Therapeutics, Inc. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Voyager Therapeutics CSO Carter Todd Alfred Sells 3,525 Shares
What Happened Carter Todd Alfred, Chief Scientific Officer of Voyager Therapeutics (VYGR), sold 3,525 shares of common stock on Feb 10, 2026. The sale was reported at a weighted average price of $3.85 per share for total proceeds of approximately $13,571. This was a sale (not a purchase) and—per the filing—was executed to satisfy tax withholding associated with the vesting of restricted stock units (RSUs), not a discretionary trade by the insider.
Key Details
- Transaction date: 2026-02-10 (Form 4 filed 2026-02-11; no late filing indicated).
- Shares sold: 3,525; weighted average price: $3.85; total proceeds: ~$13,571.
- Price range: shares were sold in multiple transactions at prices between $3.71 and $3.91.
- Reason/footnote: Sold pursuant to a durable automatic sales instruction as a sell-to-cover to satisfy tax withholding on RSUs that vested Feb 9, 2026 (not discretionary).
- Shares owned after transaction: Not reported in this Form 4.
- Reporting/footnote offer: The filer can provide a breakdown of the number of shares sold at each price on request to the company or SEC staff.
Context This was a routine sell-to-cover tied to RSU vesting—common for insiders when shares vest and taxes are due. Such transactions are typically administrative and do not necessarily indicate a change in the insider’s view of the company.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-10$3.85/sh−3,525$13,571→ 153,193 total
Footnotes (2)
- [F1]Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.71 to $3.91, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.